grants free access to help with drug design for COVID-19

We have released free access to’s synthetic accessibility screening (SAS) capabilities for every team involved in developing potential treatments and cures for COVID-19. We encourage teams working on de novo small molecule drug discovery to get in touch and start using our platform to validate their ideas.

For more information, please have a look at the press release.

Request access

How to access our software

For the time being, you have to let us know by email that you want access.

1. Send us a request.

Please send your request to [email protected].

2. We will activate your account.

We will get back to you to discuss details of your access and get you an API key as soon as possible.

3. You can use our services.

You may use our services at no costs for the purpose of developing a treatment or cure for COVID-19.